Close Menu

NEW YORK (360Dx) – T2 Biosystems announced today that it has priced a public offering of 6.1 million shares of its common stock at a public offering price of $7.50 per share, bringing in gross proceeds of roughly $45.8 million.

T2 Bio said that it will grant the underwriters a 30-day option to purchase up to an additional 915,000 shares of its common stock at the public offering price. The firm expects the offering to close around June 4.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Sponsored by

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.